Dyne Therapeutics Inc (NAS:DYN)
$ 26 0.05 (0.19%) Market Cap: 2.27 Bil Enterprise Value: 1.84 Bil PE Ratio: 0 PB Ratio: 4.68 GF Score: 36/100

Dyne Therapeutics Inc at Jefferies CNS & Neuro Summit Transcript

Oct 12, 2023 / 01:30PM GMT
Release Date Price: $7.81 (-6.86%)
Mack Chandler
Jefferies LLC - Analyst

All right, well, thank you, everyone who's here and joining us virtually as well. My name is Mack Chandler. I'm with Jefferies Research. I'm joined by Dyne Therapeutics here. We have Oxana Beskrovnaya, the Chief Science Officer; Wildon Farwell, the Chief Medical Officer; and Rob Lauzen, the Vice President of Investor Relations and Head of FP&A.

Questions & Answers

Mack Chandler
Jefferies LLC - Analyst

So thank you all for joining us today. We're very excited about the upcoming data that Dyne will present here shortly. Before we get into some of the programs and our expectations or your expectations for them, Wildon or Oxana, would mind just giving us a quick overview of the FORCE platform and the rationale behind the design of DYNE-101 and DYNE-101?

Oxana Beskrovnaya
Dyne Therapeutics, Inc. - Chief Scientific Officer

Thank you for your question. DYNE was designed with one question to solve. It's enable delivery of powerful therapeutics such as oligonucleotides

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot